JMP Securities Reiterates Market Outperform on Acrivon Therapeutics, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Acrivon Therapeutics (NASDAQ:ACRV) and maintained a $14 price target.
April 01, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities reiterates a Market Outperform rating on Acrivon Therapeutics with a $14 price target.
The reiteration of a Market Outperform rating and a maintained price target of $14 by JMP Securities indicates a strong positive outlook on Acrivon Therapeutics by the analyst. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100